NKTX — Nkarta Inc
NASDAQ · Healthcare · Biotechnology
$2.60
-$0.10 (-3.70%)
Nkarta Inc (NKTX) is a biotechnology company listed on NASDAQ. It is led by Paul J. Hastings, based in 1150 Veterans Boulevard, South San Francisco, CA, United States, 94080, with about 108 employees. Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Net income was -$76.7M. NKTX currently screens at market cap $188.9M.
Use this NKTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NKTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NKTX SEC filings page. Lician reads the product cache first so this HTML stays unique to Nkarta Inc even when a live quote feed is slow.
About Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NKTX Key Statistics
Market Cap
$188.88M
Volume
456,453
Previous Close
$2.59
Day Range
$2.58 – $2.75
P/B Ratio
0.66
EPS
-$1.60
Revenue
$0.00
Net Income
-$108.79M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
108
NKTX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$108.79M | -$117.50M | -$113.84M | -$86.08M |
| EPS (Diluted) | -$1.60 | -$2.40 | -$2.61 | -$2.62 |
Total Assets
$501.20M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$27.87M
Operating Cash Flow
-$99.70M
Free Cash Flow
$0.00
Nkarta Inc Company Information
- CEO & Director
- Paul J. Hastings
- Headquarters
- 1150 Veterans Boulevard, South San Francisco, CA, United States, 94080
- Website
- www.nkartatx.com
- Phone
- 925 407 1049
- IPO / Founded
- 2020-07-10
- Sector
- Healthcare
- Industry
- Biotechnology